Dr. John Cush RheumNow
3 years 2 months ago
Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/6OVZhkTdGc https://t.co/3VHhI7nfQm
A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
Dr. John Cush RheumNow
3 years 2 months ago
Assessing CV Risk in Inflammatory Arthritis: Which Score?
Dr. Aurelie Najm discusses OP0267 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo
https://t.co/qlJ9iMwrip
@AurelieRheumo https://t.co/Yh2siy6555
Dr. John Cush RheumNow
3 years 2 months ago
Abatacept: is there a role before RA hits?
Dr. David Liew discusses OP0130 at EULAR 2023 in Milan, Italy. @drdavidliew
https://t.co/SPLOCjjhUt https://t.co/wkPJLz9ctg
Dr. John Cush RheumNow
3 years 2 months ago
ANCA-associated vasculitis: beyond therapy with rituximab?
AAV is a group of multi-system autoimmune small vessel vasculitides which includes GPA, MPA and EGPA.
https://t.co/eZ3mgdjrEp https://t.co/dM9B4tVgmr
Dr. John Cush RheumNow
3 years 2 months ago
Methotrexate - an old trusted friend who deserves better
MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice.
https://t.co/xp40KklMkA https://t.co/oVqzlQeqbe
Dr. John Cush RheumNow
3 years 2 months ago
RheumNow Eular2023 Coverage - SLE Panel Discussion https://t.co/pLWOqZo2aw https://t.co/itAOjgmMTl
Dr. John Cush RheumNow
3 years 2 months ago
AOSD: Young vs. Elderly Onset
AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.
https://t.co/fg5TakEvvv https://t.co/lu34gX7WTZ
Dr. John Cush RheumNow
3 years 2 months ago
EULAR 2023 Notes from Milan
Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy
https://t.co/brcgGv2GHD https://t.co/zVyZkEuLy4
Dr. John Cush RheumNow
3 years 2 months ago
Assessing CV Risk in Inflammatory Arthritis: Which Score?
Dr. Aurelie Najm discusses OP0267 presented at EULAR 2023 in Milan, Italy.
https://t.co/MvqkKya4vm
@AurelieRheumo
Dr. John Cush RheumNow
3 years 2 months ago
Combining a Tyk2 inhibitor with a JAKi in RA?
Dr. Janet Pope (@Janetbirdope ) weighs in on #EULAR23 abstracts.
https://t.co/7fTZjvnHT3 https://t.co/o43VrWpVpI
Dr. John Cush RheumNow
3 years 2 months ago
A step change towards self-empowerment for people living with SLE
As I reflect on my research journey, I recall several issues that still need to be addressed in the management of SLE.
https://t.co/ElunbUgSGF https://t.co/YmA1YWPxVP
Dr. John Cush RheumNow
3 years 2 months ago
Postpartum Depression in RA
Dr. Jonathan Kay discusses abstract POS0206-HPR at EULAR 2023 in Milan, Italy.
https://t.co/dzUMIia8Q6 https://t.co/IjeEvz8Cab
